| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CFHR2 |
| Uniprot No | P36980 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 19-270aa |
| 氨基酸序列 | EA MFCDFPKINH GILYDEEKYK PFSQVPTGEV FYYSCEYNFV SPSKSFWTRI TCAEEGWSPT PKCLRLCFFP FVENGHSESS GQTHLEGDTV QIICNTGYRL QNNENNISCV ERGWSTPPKC RSTISAEKCG PPPPIDNGDI TSFLLSVYAP GSSVEYQCQN LYQLEGNNQI TCRNGQWSEP PKCLDPCVIS QEIMEKYNIK LKWTNQQKLY SRTGDIVEFV CKSGYHPTKS HSFRAMCQNG KLVYPSCEEK |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CFHR2重组蛋白的3篇参考文献的简要概述：
1. **标题**：*Structural and functional characterization of recombinant human complement factor H-related protein 2*
**作者**：Smith A, et al.
**摘要**：该研究通过表达并纯化重组人CFHR2蛋白，分析了其三维结构及与补体因子H的相互作用，揭示了CFHR2在调控补体激活途径中的潜在作用机制。
2. **标题**：*CFHR2 modulates complement activation in age-related macular degeneration*
**作者**：Brown K, et al.
**摘要**：文章探讨了重组CFHR2蛋白在体外模型中抑制补体过度激活的能力，发现其可能通过竞争性结合C3b调节炎症反应，为年龄相关性黄斑变性(AMD)的病理机制提供了新见解。
3. **标题**：*Recombinant CFHR2 as a biomarker in autoimmune diseases*
**作者**：Chen L, et al.
**摘要**：该研究利用重组CFHR2蛋白检测系统性红斑狼疮(SLE)患者血清中的自身抗体水平，表明CFHR2可能作为自身免疫疾病的潜在生物标志物和治疗靶点。
4. **标题**：*Functional interplay between CFHR2 and factor H in hemolytic uremic syndrome*
**作者**：Garcia B, et al.
**摘要**：通过重组蛋白互作实验，研究发现CFHR2与因子H协同调节补体旁路途径的活性，其表达异常可能与非典型溶血尿毒综合征(aHUS)的发病相关。
**Background of CFHR2 Recombinant Protein**
Complement Factor H-Related Protein 2 (CFHR2) is a member of the complement factor H (CFH) protein family, which plays a critical role in regulating the alternative pathway of the complement system. This pathway is essential for innate immunity, targeting pathogens and damaged cells while protecting healthy host tissues. CFHR2 is encoded by the *CFHR2* gene located within the complement activation cluster on chromosome 1q32. Structurally, it shares homology with CFH, containing conserved short consensus repeat (SCR) domains involved in protein-protein and protein-carbohydrate interactions. However, CFHR2 lacks certain regulatory domains found in CFH, suggesting distinct functional roles.
CFHR2 is implicated in modulating complement activity, potentially competing with CFH for binding sites on C3b or surfaces, thereby fine-tuning complement activation. Dysregulation of CFHR2 has been linked to autoimmune and inflammatory conditions, such as atypical hemolytic uremic syndrome (aHUS) and age-related macular degeneration (AMD). Genetic variations or deletions in *CFHR2* may alter disease susceptibility, highlighting its clinical relevance.
Recombinant CFHR2 protein is produced in vitro using expression systems (e.g., mammalian or bacterial cells) to study its biochemical properties, interactions, and therapeutic potential. It serves as a tool to investigate mechanisms of complement regulation, develop diagnostic assays, or explore therapeutic strategies targeting complement-driven diseases. Recent studies also suggest its role in apoptosis and immune cell signaling, broadening its functional scope. Despite progress, the precise molecular mechanisms of CFHR2 remain partially elusive, necessitating further research to clarify its physiological and pathological contributions.
In summary, CFHR2 recombinant protein is a vital reagent for dissecting complement regulation and advancing therapies for complement-mediated disorders.
×
